On-Demand Webinar

How to Choose Your First-in-Human Dose Approach

MABEL, PK/PD, mPAD, PBPK, or QSP? Certara scientists on matching your first-in-human dose prediction approach…

CertaraAugust 17, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

Blog

A model-informed approach to radioligand therapy dosing under Project Optimus

Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…

Hunter Stephens, PhDAugust 13, 2026

White Paper

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…

Katie Owens, PhDAugust 12, 2026

On-Demand Webinar

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Investors, founders, and drug development strategists on what makes an early-stage biotech investable beyond the…

CertaraAugust 6, 2026

Publication

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…

CertaraJuly 29, 2026

Poster

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…

CertaraJuly 20, 2026

Conference

EANM 2026

–

Danielle PillsburyJuly 20, 2026

On-Demand Webinar

From Dosimetry to Dose Decisions: How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Learn how dosimetry, clinical pharmacology, pharmacometrics, QSP, and regulatory strategy support dose optimization for therapeutic…

Hunter Stephens, PhDJuly 17, 2026

Publication

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…

CertaraJuly 16, 2026

Drug Development

How to Choose Your First-in-Human Dose Approach

MBMA data curation: How AI and expert meta-analysts get it right, fast

A model-informed approach to radioligand therapy dosing under Project Optimus

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

EANM 2026

From Dosimetry to Dose Decisions: How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Newsletter sign up

Quick links

Solutions

Contact